Alison Abraham
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 51 | 2024 | 2812 | 4.310 |
Why?
| | Cognitive Dysfunction | 6 | 2023 | 385 | 2.500 |
Why?
| | Sexual and Gender Minorities | 6 | 2021 | 213 | 2.210 |
Why?
| | Retinal Vessels | 4 | 2022 | 69 | 2.190 |
Why?
| | Renal Insufficiency, Chronic | 14 | 2024 | 611 | 1.650 |
Why?
| | Dry Eye Syndromes | 5 | 2024 | 54 | 1.540 |
Why?
| | Glomerular Filtration Rate | 19 | 2024 | 744 | 1.390 |
Why?
| | Homosexuality, Male | 8 | 2021 | 182 | 1.360 |
Why?
| | Tomography, Optical Coherence | 3 | 2023 | 212 | 1.350 |
Why?
| | Viral Load | 10 | 2021 | 460 | 1.240 |
Why?
| | Cognition Disorders | 2 | 2023 | 515 | 1.180 |
Why?
| | Antiretroviral Therapy, Highly Active | 9 | 2018 | 269 | 1.170 |
Why?
| | Vision Disorders | 4 | 2023 | 141 | 1.150 |
Why?
| | Hearing Loss | 4 | 2023 | 220 | 1.030 |
Why?
| | Depression | 4 | 2020 | 1402 | 1.000 |
Why?
| | Bias | 4 | 2022 | 218 | 0.930 |
Why?
| | Vitamin D Deficiency | 2 | 2017 | 184 | 0.930 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 232 | 0.910 |
Why?
| | AIDS-Associated Nephropathy | 4 | 2017 | 7 | 0.890 |
Why?
| | Anti-HIV Agents | 7 | 2018 | 772 | 0.870 |
Why?
| | Atherosclerosis | 4 | 2022 | 415 | 0.870 |
Why?
| | Masks | 1 | 2023 | 62 | 0.810 |
Why?
| | Cognitive Aging | 1 | 2023 | 16 | 0.800 |
Why?
| | Hypertension | 6 | 2023 | 1284 | 0.790 |
Why?
| | Fluorescein Angiography | 2 | 2022 | 150 | 0.770 |
Why?
| | CD4 Lymphocyte Count | 11 | 2021 | 267 | 0.770 |
Why?
| | Cohort Studies | 26 | 2023 | 5718 | 0.760 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1033 | 0.760 |
Why?
| | Eye | 1 | 2023 | 108 | 0.750 |
Why?
| | Male | 59 | 2023 | 67361 | 0.690 |
Why?
| | Cross-Sectional Studies | 19 | 2023 | 5417 | 0.680 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2020 | 12 | 0.660 |
Why?
| | Aged | 26 | 2023 | 23729 | 0.650 |
Why?
| | Glaucoma | 1 | 2023 | 234 | 0.640 |
Why?
| | Humans | 87 | 2024 | 136783 | 0.620 |
Why?
| | Cognition | 4 | 2023 | 1166 | 0.610 |
Why?
| | Middle Aged | 46 | 2021 | 33200 | 0.600 |
Why?
| | Viremia | 2 | 2018 | 138 | 0.590 |
Why?
| | Crime Victims | 1 | 2020 | 129 | 0.570 |
Why?
| | HIV | 6 | 2020 | 233 | 0.560 |
Why?
| | Body Size | 1 | 2018 | 108 | 0.560 |
Why?
| | Vitamin D | 2 | 2018 | 395 | 0.550 |
Why?
| | Kidney Diseases | 4 | 2014 | 406 | 0.530 |
Why?
| | Kidney | 12 | 2024 | 1463 | 0.520 |
Why?
| | Survivors | 1 | 2020 | 487 | 0.520 |
Why?
| | Hepatitis C | 4 | 2023 | 263 | 0.500 |
Why?
| | Immunologic Factors | 1 | 2018 | 237 | 0.500 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2018 | 548 | 0.480 |
Why?
| | Kidney Failure, Chronic | 3 | 2017 | 565 | 0.470 |
Why?
| | Dementia | 1 | 2019 | 252 | 0.470 |
Why?
| | Risk Factors | 25 | 2024 | 10331 | 0.460 |
Why?
| | Body Composition | 2 | 2018 | 677 | 0.460 |
Why?
| | Microbiota | 1 | 2023 | 761 | 0.460 |
Why?
| | Prospective Studies | 19 | 2022 | 7583 | 0.450 |
Why?
| | Depressive Disorder | 1 | 2018 | 380 | 0.450 |
Why?
| | Aging | 3 | 2023 | 1861 | 0.440 |
Why?
| | Female | 48 | 2024 | 72840 | 0.430 |
Why?
| | Attention | 1 | 2017 | 435 | 0.420 |
Why?
| | Executive Function | 2 | 2023 | 448 | 0.420 |
Why?
| | Biomarkers | 14 | 2024 | 4158 | 0.400 |
Why?
| | Adult | 44 | 2023 | 37616 | 0.380 |
Why?
| | Substance-Related Disorders | 1 | 2021 | 1072 | 0.380 |
Why?
| | Stress, Psychological | 1 | 2020 | 1098 | 0.370 |
Why?
| | Prevalence | 7 | 2022 | 2712 | 0.360 |
Why?
| | Anemia | 1 | 2012 | 170 | 0.340 |
Why?
| | Comorbidity | 4 | 2021 | 1611 | 0.330 |
Why?
| | Longitudinal Studies | 6 | 2022 | 2847 | 0.320 |
Why?
| | Independent Living | 2 | 2022 | 103 | 0.320 |
Why?
| | United States | 18 | 2024 | 14660 | 0.320 |
Why?
| | Creatinine | 9 | 2023 | 498 | 0.310 |
Why?
| | Metabolomics | 3 | 2023 | 679 | 0.300 |
Why?
| | Hospitals | 2 | 2023 | 677 | 0.300 |
Why?
| | Aged, 80 and over | 8 | 2023 | 7569 | 0.290 |
Why?
| | Neuropsychological Tests | 4 | 2022 | 1054 | 0.290 |
Why?
| | Bone Density | 2 | 2022 | 487 | 0.280 |
Why?
| | Incidence | 9 | 2022 | 2788 | 0.250 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1942 | 0.230 |
Why?
| | Iohexol | 2 | 2015 | 23 | 0.230 |
Why?
| | HIV-1 | 5 | 2017 | 857 | 0.230 |
Why?
| | Renal Insufficiency | 2 | 2017 | 156 | 0.220 |
Why?
| | Kidney Function Tests | 4 | 2017 | 159 | 0.220 |
Why?
| | Tears | 1 | 2023 | 28 | 0.210 |
Why?
| | Genes, rRNA | 1 | 2023 | 41 | 0.200 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 57 | 0.200 |
Why?
| | Ophthalmic Solutions | 1 | 2023 | 75 | 0.200 |
Why?
| | Cornea | 1 | 2023 | 136 | 0.200 |
Why?
| | Optic Disk | 1 | 2023 | 44 | 0.190 |
Why?
| | Dietary Proteins | 1 | 2023 | 135 | 0.190 |
Why?
| | RNA, Viral | 4 | 2020 | 651 | 0.190 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2022 | 59 | 0.190 |
Why?
| | Metabolome | 2 | 2023 | 350 | 0.190 |
Why?
| | Drug Users | 1 | 2022 | 39 | 0.190 |
Why?
| | Cancellous Bone | 1 | 2021 | 23 | 0.190 |
Why?
| | Epidemiologic Studies | 1 | 2022 | 72 | 0.190 |
Why?
| | Pseudouridine | 1 | 2021 | 4 | 0.190 |
Why?
| | Hypotension | 1 | 2023 | 122 | 0.180 |
Why?
| | Uridine | 1 | 2021 | 30 | 0.180 |
Why?
| | DNA, Bacterial | 1 | 2023 | 336 | 0.180 |
Why?
| | Femur Neck | 1 | 2021 | 63 | 0.180 |
Why?
| | Alpha-Globulins | 3 | 2017 | 20 | 0.180 |
Why?
| | Alcohol Drinking | 2 | 2019 | 818 | 0.180 |
Why?
| | Ascaris | 1 | 2020 | 2 | 0.170 |
Why?
| | Odds Ratio | 4 | 2018 | 1063 | 0.170 |
Why?
| | North America | 3 | 2017 | 313 | 0.170 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2023 | 549 | 0.170 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 56 | 0.170 |
Why?
| | Age Factors | 5 | 2020 | 3290 | 0.170 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2021 | 2512 | 0.170 |
Why?
| | Visual Acuity | 1 | 2022 | 348 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2024 | 250 | 0.160 |
Why?
| | Survival Analysis | 3 | 2018 | 1319 | 0.160 |
Why?
| | Adenosine | 1 | 2021 | 226 | 0.160 |
Why?
| | Sex Factors | 4 | 2018 | 2068 | 0.160 |
Why?
| | Malnutrition | 1 | 2020 | 82 | 0.160 |
Why?
| | Serum Albumin | 2 | 2024 | 149 | 0.160 |
Why?
| | Kidney Transplantation | 2 | 2017 | 700 | 0.160 |
Why?
| | Disease Progression | 7 | 2023 | 2750 | 0.160 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 307 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2020 | 91 | 0.150 |
Why?
| | Interleukin-18 | 5 | 2024 | 237 | 0.150 |
Why?
| | Inpatients | 1 | 2023 | 499 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5115 | 0.150 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2019 | 91 | 0.150 |
Why?
| | Prognosis | 5 | 2018 | 4018 | 0.150 |
Why?
| | Epidemiologic Research Design | 1 | 2018 | 29 | 0.140 |
Why?
| | Prediabetic State | 1 | 2021 | 253 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 2 | 2017 | 114 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 2019 | 96 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2022 | 596 | 0.140 |
Why?
| | Bisexuality | 1 | 2018 | 31 | 0.140 |
Why?
| | Hand Strength | 2 | 2022 | 122 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2021 | 346 | 0.140 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2016 | 125 | 0.140 |
Why?
| | Acetylglucosaminidase | 2 | 2016 | 5 | 0.140 |
Why?
| | Cystatin C | 2 | 2016 | 65 | 0.140 |
Why?
| | Case-Control Studies | 6 | 2023 | 3537 | 0.130 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 40 | 0.130 |
Why?
| | Dihydroxycholecalciferols | 1 | 2016 | 1 | 0.130 |
Why?
| | Coronary Artery Disease | 1 | 2023 | 702 | 0.130 |
Why?
| | Hypercholesterolemia | 1 | 2018 | 105 | 0.130 |
Why?
| | Tenofovir | 2 | 2016 | 240 | 0.130 |
Why?
| | HIV Seropositivity | 2 | 2017 | 125 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2023 | 15564 | 0.130 |
Why?
| | Geriatric Assessment | 1 | 2018 | 218 | 0.130 |
Why?
| | Machine Learning | 1 | 2022 | 487 | 0.130 |
Why?
| | Time Factors | 5 | 2018 | 6792 | 0.130 |
Why?
| | Albuminuria | 4 | 2023 | 185 | 0.130 |
Why?
| | Acute-Phase Proteins | 2 | 2013 | 67 | 0.130 |
Why?
| | Lipocalins | 2 | 2013 | 36 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 349 | 0.130 |
Why?
| | HIV Wasting Syndrome | 1 | 2016 | 4 | 0.130 |
Why?
| | Geography | 1 | 2016 | 197 | 0.120 |
Why?
| | Hemoglobins | 2 | 2020 | 353 | 0.120 |
Why?
| | Inflammation | 3 | 2018 | 2834 | 0.120 |
Why?
| | Alzheimer Disease | 1 | 2021 | 557 | 0.120 |
Why?
| | Young Adult | 9 | 2023 | 13126 | 0.120 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 283 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 278 | 0.120 |
Why?
| | Patient Care | 1 | 2016 | 110 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 33 | 0.110 |
Why?
| | Living Donors | 1 | 2017 | 295 | 0.110 |
Why?
| | Adolescent | 10 | 2023 | 21463 | 0.110 |
Why?
| | Immune Tolerance | 1 | 2017 | 362 | 0.110 |
Why?
| | Arsenic | 1 | 2015 | 65 | 0.110 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 77 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3272 | 0.110 |
Why?
| | Factor Analysis, Statistical | 1 | 2015 | 286 | 0.110 |
Why?
| | Canada | 4 | 2017 | 420 | 0.110 |
Why?
| | HIV Seronegativity | 1 | 2013 | 28 | 0.110 |
Why?
| | Kidney Tubules, Proximal | 1 | 2014 | 127 | 0.110 |
Why?
| | Models, Theoretical | 1 | 2017 | 572 | 0.110 |
Why?
| | Lipodystrophy | 1 | 2013 | 13 | 0.100 |
Why?
| | Kidney Glomerulus | 1 | 2014 | 114 | 0.100 |
Why?
| | Graft Rejection | 1 | 2017 | 620 | 0.100 |
Why?
| | beta 2-Microglobulin | 1 | 2013 | 50 | 0.100 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2013 | 84 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 646 | 0.100 |
Why?
| | Organophosphonates | 1 | 2013 | 92 | 0.100 |
Why?
| | Antibodies, Fungal | 1 | 2011 | 9 | 0.090 |
Why?
| | Pneumocystis carinii | 1 | 2011 | 11 | 0.090 |
Why?
| | Patient Compliance | 1 | 2015 | 576 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2015 | 434 | 0.090 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2011 | 37 | 0.090 |
Why?
| | Dyslipidemias | 1 | 2013 | 176 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2108 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 468 | 0.090 |
Why?
| | Adenine | 1 | 2013 | 267 | 0.090 |
Why?
| | Baltimore | 2 | 2021 | 58 | 0.090 |
Why?
| | Motor Activity | 1 | 2016 | 719 | 0.090 |
Why?
| | Fungal Proteins | 1 | 2011 | 134 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 806 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 649 | 0.080 |
Why?
| | Risk Assessment | 3 | 2018 | 3429 | 0.080 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 3 | 2016 | 42 | 0.080 |
Why?
| | Lipocalin-2 | 3 | 2016 | 79 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 2030 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2831 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 811 | 0.080 |
Why?
| | Child | 7 | 2023 | 21968 | 0.070 |
Why?
| | Homicide | 1 | 2008 | 66 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 976 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1260 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5749 | 0.070 |
Why?
| | Brain | 1 | 2019 | 2669 | 0.070 |
Why?
| | Hepacivirus | 2 | 2022 | 258 | 0.060 |
Why?
| | Membrane Glycoproteins | 3 | 2013 | 500 | 0.060 |
Why?
| | Child, Preschool | 4 | 2023 | 11069 | 0.060 |
Why?
| | Primary Health Care | 1 | 2015 | 1714 | 0.060 |
Why?
| | Stroke | 1 | 2013 | 1129 | 0.060 |
Why?
| | Diet, Protein-Restricted | 1 | 2023 | 11 | 0.050 |
Why?
| | Population Surveillance | 2 | 2017 | 470 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2018 | 10764 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2022 | 6 | 0.050 |
Why?
| | Intelligence | 1 | 2023 | 130 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2022 | 9 | 0.050 |
Why?
| | Meibomian Glands | 1 | 2022 | 18 | 0.050 |
Why?
| | Receptors, Virus | 2 | 2013 | 83 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2014 | 532 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2023 | 241 | 0.050 |
Why?
| | Research Design | 2 | 2021 | 1107 | 0.050 |
Why?
| | Tobramycin | 1 | 2022 | 51 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2023 | 110 | 0.050 |
Why?
| | Support Vector Machine | 1 | 2022 | 38 | 0.050 |
Why?
| | Neoplasms | 1 | 2017 | 2644 | 0.050 |
Why?
| | Sugar Acids | 1 | 2021 | 4 | 0.050 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2022 | 47 | 0.050 |
Why?
| | Citrates | 1 | 2021 | 44 | 0.050 |
Why?
| | Cyclosporine | 1 | 2022 | 268 | 0.050 |
Why?
| | Linear Models | 2 | 2014 | 845 | 0.040 |
Why?
| | Hearing | 1 | 2022 | 118 | 0.040 |
Why?
| | Infant | 3 | 2023 | 9442 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 172 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2023 | 255 | 0.040 |
Why?
| | Eating | 1 | 2023 | 378 | 0.040 |
Why?
| | Renal Replacement Therapy | 1 | 2021 | 92 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2022 | 182 | 0.040 |
Why?
| | Sulfides | 1 | 2021 | 99 | 0.040 |
Why?
| | Alanine | 1 | 2021 | 151 | 0.040 |
Why?
| | Los Angeles | 1 | 2020 | 76 | 0.040 |
Why?
| | Audiometry, Pure-Tone | 1 | 2020 | 30 | 0.040 |
Why?
| | Tryptophan | 1 | 2021 | 183 | 0.040 |
Why?
| | Cataract | 1 | 2022 | 213 | 0.040 |
Why?
| | Microcirculation | 1 | 2020 | 145 | 0.040 |
Why?
| | Frailty | 1 | 2022 | 170 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2021 | 317 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 551 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1919 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 400 | 0.040 |
Why?
| | Blood Glucose | 2 | 2021 | 2180 | 0.040 |
Why?
| | Heterosexuality | 1 | 2018 | 43 | 0.040 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 189 | 0.030 |
Why?
| | Multimorbidity | 1 | 2018 | 47 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1019 | 0.030 |
Why?
| | Logistic Models | 1 | 2022 | 2060 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1455 | 0.030 |
Why?
| | Nephrectomy | 1 | 2017 | 168 | 0.030 |
Why?
| | History, 21st Century | 1 | 2017 | 211 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 130 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1281 | 0.030 |
Why?
| | Blood Pressure | 1 | 2023 | 1772 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1273 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2016 | 70 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2016 | 328 | 0.030 |
Why?
| | Demography | 1 | 2016 | 291 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 751 | 0.030 |
Why?
| | Apolipoprotein L1 | 1 | 2014 | 13 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 533 | 0.030 |
Why?
| | Risk | 1 | 2017 | 904 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1619 | 0.030 |
Why?
| | Proteinuria | 1 | 2014 | 97 | 0.030 |
Why?
| | Health | 1 | 2014 | 84 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2015 | 267 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2014 | 170 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2016 | 443 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2018 | 763 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2014 | 219 | 0.020 |
Why?
| | Health Policy | 1 | 2016 | 387 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 164 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1347 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2013 | 203 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2013 | 253 | 0.020 |
Why?
| | Alleles | 1 | 2014 | 888 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 410 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1513 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2013 | 366 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 411 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2011 | 123 | 0.020 |
Why?
| | Triglycerides | 1 | 2013 | 524 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2011 | 288 | 0.020 |
Why?
| | Animals | 2 | 2023 | 36768 | 0.020 |
Why?
| | Social Problems | 1 | 2008 | 12 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 849 | 0.020 |
Why?
| | Tanzania | 1 | 2008 | 58 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2013 | 778 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2013 | 629 | 0.020 |
Why?
| | Age Distribution | 1 | 2008 | 391 | 0.020 |
Why?
| | Sex Distribution | 1 | 2008 | 376 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1784 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2011 | 886 | 0.020 |
Why?
| | Cause of Death | 1 | 2008 | 429 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2417 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2013 | 1201 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2677 | 0.010 |
Why?
|
|
Abraham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|